New research indicates that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop traditional diet and exercise plans.
Research printed in a leading medical journal demonstrates that while overweight people frequently drop substantial amounts of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be cognizant of the risk of quick weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a reversion to starting weight within about a year and a half.
Weighing Therapies
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists note that individuals who shed pounds through dieting usually see a less rapid creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Experts believe the mode of action of the injections accounts for the amplified weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to produce less of its endogenous hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making overeating a significant risk."
A Chronic Issue?
Medical guidelines advise the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the therapy might need to be long-term.
This opinion is reinforced by drug manufacturers, who state that the findings "emphasize the chronic character of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
Users who have stopped the jabs describe a sudden resurgence of hunger.
"I experienced something that goes on and you're instantly starving," recalled a patient.
This difficulty is worsened if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Significant Interest
Survey data show that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is greater among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on combined lifestyle support.
